Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | LPL | P06858 | 6/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL553104 | 0.85 | LPL (0.43) | LPLLIPGGSK3AGSK3BF11 | |
| SCHEMBL552697 | 0.83 | KCNH2 (0.38) | AAK1LPLLIPGGSK3AGSK3B | |
| SCHEMBL3798379 | 0.81 | LPL (0.38) | LPLLIPGGSK3AGSK3BF11 | |
| SCHEMBL552720 | 0.81 | FFAR1 (0.37) | AAK1LPLLIPGGSK3AGSK3B | |
| SCHEMBL552417 | 0.80 | LPL (0.34) | AAK1LPLLIPGGSK3AGSK3B | |
| SCHEMBL552139 | 0.79 | GSK3A (0.35) | LPLLIPGGSK3AGSK3BF11 | |
| SCHEMBL552832 | 0.79 | L3MBTL1 (0.36) | LPLLIPGGSK3AGSK3BF11 | |
| SCHEMBL552872 | 0.78 | ESR2 (0.34) | LPLLIPGGSK3AGSK3BF11 | |
| SCHEMBL552083 | 0.77 | SCN8A (0.37) | LPLLIPGGSK3AGSK3B | |
| SCHEMBL2428673 | 0.76 | LIPG (0.45) | AAK1LPLLIPGGSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354406-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120035164-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-02-09 | — | — | US | disclosed |
| US-8063071-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090143372-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-06-04 | — | — | US | disclosed |
| EP-1896014-A2 | CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007005534-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035164-A1 | CHEMICAL COMPOUNDS | IKBKG, NFKBIA, RELA | AAK1 1584/4885LPL 4845/4885LIPG 4457/4885 |
| US-20090143372-A1 | CHEMICAL COMPOUNDS | IKBKG, NFKBIA, RELA | AAK1 1584/4885LPL 4845/4885LIPG 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.